UroGen Pharma (URGN) Net Cash Flow (2017 - 2026)

UroGen Pharma (URGN) has reported Net Cash Flow for 10 consecutive years, with -$800000.0 the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 98.82% year-over-year to -$800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 122.78% YoY) and the FY2025 annual result came in at -$61.0 million, down 178.93% from the prior year.
• Net Cash Flow fell to -$800000.0 in Q1 2026 per URGN's latest filing, from $20.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for URGN reached as high as $99.2 million in Q3 2023 and fell as low as -$94.8 million in Q3 2024.
• A 5-year average of $3.9 million and a median of -$2.6 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 551.35% — and 2024, when it jumped 639.49%.
• Year by year, Net Cash Flow stood at $26.7 million in 2022, then sank by 190.93% to -$24.3 million in 2023, then surged by 293.72% to $47.1 million in 2024, then tumbled by 56.01% to $20.7 million in 2025, then plunged by 103.86% to -$800000.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$800000.0, $20.7 million, and -$2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.